4-{4-[(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid

• ChemBase编号: 4396
• 分子式: C21H25ClN2O3
• 平均质量: 388.8878
• 单一同位素质量: 388.15537035
• SMILES: Clc1ccc(C(OC2CCN(CC2)CCCC(=O)O)c2ncccc2)cc1
• Canonical SMILES: OC(=O)CCCN1CCC(CC1)OC(c1ccccn1)c1ccc(cc1)Cl
• InChI: InChI=1S/C21H25ClN2O3/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-10-14-24(15-11-18)13-3-5-20(25)26/h1-2,4,6-9,12,18,21H,3,5,10-11,13-15H2,(H,25,26)
• InChIKey: YWGDOWXRIALTES-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 4-{4-[(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid
• IUPAC传统名: @bepotastine
• 商标名: Talion
• 别名: Bepotastine besilate; Betotastine besilate; TAU-284DS; bepotastine; Bepotastine

登记号

• CAS号: 190786-44-8
• PubChem SID: 160967828; 46504940
• PubChem CID: 2350

理论计算性质

JChem

• Acid pKa: 4.1016054
• 质子受体: 5
• 质子供体: 1
• LogD (pH = 5.5): 0.5400221
• LogD (pH = 7.4): 0.5506054
• Log P: 0.55255556
• 摩尔折射率: 105.0988 cm^3
• 极化性: 41.298424 Å^3
• 极化表面积: 62.66 Å^2
• 可自由旋转的化学键: 8
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 3.64
• LOG S: -3.89
• 溶解度: 5.03e-02 g/l

详细说明

DrugBank - DB04890

• Drug Groups: approved; investigational
• Description: Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion®. It is currently undergoing trials in the U.S.
• Indication: For the treatment of allergic conjunctivitis and uriticaria/puritus.
• Pharmacology: Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. It has a stabilizing effect on mast cells, and it suppresses the migration of eosinophils into inflamed tissues. Bepotastine is under investigation in an eye drop formulation by Ista for the treatment of allergic conjunctivitis. An oral formulation of this drug is approved in Japan for the treatment of allergic conjunctivitis and uriticaria/puritus. Ista Pharm. filed an IND with the FDA for bepotastine in December of 2006.
• Affected Organisms: Humans and other mammals
• Absorption: High oral absorption
• References: Ohashi R, Kamikozawa Y, Sugiura M, Fukuda H, Yabuuchi H, Tamai I: Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. Drug Metab Dispos. 2006 May;34(5):793-9. Epub 2006 Feb 2. [Pubmed] ; Andoh T, Kuraishi Y: Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice. Eur J Pharmacol. 2006 Oct 10;547(1-3):59-64. Epub 2006 Jul 25. [Pubmed]
• External Links: Drugs.com

参考文献

• Ohashi R, Kamikozawa Y, Sugiura M, Fukuda H, Yabuuchi H, Tamai I: Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. Drug Metab Dispos. 2006 May;34(5):793-9. Epub 2006 Feb 2. Pubmed
• Andoh T, Kuraishi Y: Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice. Eur J Pharmacol. 2006 Oct 10;547(1-3):59-64. Epub 2006 Jul 25. Pubmed